Alkahest, Inc.

21 articles with Alkahest, Inc.

• Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress

  3/25/2019

  Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.

• Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease

  3/18/2019

  Alkahest, Inc. announced the dosing of the first subject with severe Alzheimer's disease in a Phase 2 clinical trial of GRF6019 in collaboration with development partner Grifols.

• Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress

  3/14/2019

  Alkahest, Inc. will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST.

• Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration

  12/17/2018

  Both treatment naïve and treatment refractory individuals experienced improved visual acuity

• Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment

  12/4/2018

  Grant funding by The Michael J. Fox Foundation will support Phase 2 trial

• 

  BioSpace Movers and Shakers: Nov. 26

  11/26/2018

  In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
• 

  BioSpace Movers and Shakers Nov. 12

  11/12/2018

  Biopharma companies name new members of their leadership teams. Who made big moves this week?

• Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer

  11/7/2018

  Alkahest, Inc. today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer. 

• Alkahest to Present at the Society for Neuroscience 48th Annual Meeting

  11/5/2018

  Presentations highlight a novel multifactorial approach to treating neurodegenerative diseases

• Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine's 50 Most Influential People in Health Care

  11/2/2018

  Alkahest Inc. announced today that Tony Wyss-Coray Ph.D., Alkahest's co-founder and board member was named to TIME Health's list of individuals who were most influential in transforming healthcare in 2018.  

• Alkahest Presentation at Clinical Trials in Alzheimer's Disease (CTAD) Conference October 26, 2018, Barcelona, Spain

  10/29/2018

  Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer's Disease

• 

  19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties

  10/19/2018

  TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.

• Alkahest, Inc. Announces Key Appointment of Bruce Morimoto, PhD

  8/1/2018

  Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

• Alkahest to Present at Alzheimer's Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL

  7/23/2018

  Presentations highlight a novel multifactorial approach to the treatment of Alzheimer's Disease

• Alkahest, Inc. Announces Key Appointment

  6/18/2018

  Michael Byrnes joins Alkahest as Chief Financial Officer

• Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson's Disease

  5/21/2018

  Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) entitled "Development of ALK4290 as a novel PD therapeutic" under the Principal Investigator S. Sakura Minami, Ph.D.

• Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration

  5/14/2018

  Alkahest Inc. is a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases

• Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease

  4/25/2018

  Alkahest Inc. announced the initiation of a Phase 2 randomized, double-blinded dose response study of GRF6019 in patients with mild to moderate Alzheimer's Disease (ALK6019-201).

• Alkahest Receives Grant From Michael J. Fox Foundation; Funding Will Support the Clinical Development of a Novel Parkinson's Therapy

  2/12/2018

  GRF6019 is a plasma-derived product in clinical development for the treatment of neurodegenerative diseases.

• 

  Denali Top Exec Jumps Ship for Bay Area Anti-Aging Startup Alkahest

  1/24/2018

  Hannestad will be responsible for Alkahest's clinical programs in Alzheimer's and Parkinson's Disease.